The study aim: The purpose of this study is to measure the matrix metalloproteinase 7
INTRODUCTION
Rheumatoid arthritis (RA) is a systemic inflammatory disorder that most commonly affects the joints, causing progressive, symmetric, erosive destruction of cartilage and bone, which is usually associated with autoantibody production. Although joint disease is the main presentation, there are a number of extra-articular manifestations including subcutaneous nodule formation, vasculitis, inflammatory eye disease and lung disease. Of these manifestations, lung disease is a major contributor to morbidity and mortality 1 . Among the most significant factors contributing to this excess mortality is interstitial lung disease (ILD), the most common subtype of lung involvement in RA. In fact, the risk of death among individuals with clinically evident RA-associated ILD is 3 times higher than that among RA patients without ILD. Recent studies have further demonstrated that even though overall mortality rates in RA are declining, the rate of death due to RA-ILD has increased significantly 2 . The mechanism of pulmonary fibrosis occurring in ILD is not well understood. Patients with rheumatoid arthritis typically have circulating autoantibodies, the most common being rheumatoid factor and anti-cyclic citrullinated peptide (CCP). These antibodies may be present in the serum for several years before clinical disease onset. Both rheumatoid factor and anti-CCP have been linked to the development of ILD. There is growing evidence that rheumatoid arthritis begins in the lungs, a theory supported by a subgroup of patients who are anti-CCP positive with lung disease but have no articular manifestations 3 . The matrix metalloproteinases (MMPs) are thought to be key enzymes involved in remodeling of the extracellular matrix (ECM) in physiological and pathological situations (e.g. arthritis, cancer, atherosclerosis, and periodontal disease)
.
Recent reports indicate that matrix metalloproteinase-7 (MMP-7) is a potential diagnostic and prognostic marker of interstitial pulmonary fibrosis (IPF). MMP-7 has been shown to be upregulated in the lungs in IPF, particularly in alveolar macrophages and hyperplastic epithelial cells. Bronchoalveolar lavage fluid (BALF) and serum levels of MMP-7 are significantly higher in patients with IPF compared with those in healthy subjects. Elevated levels of serum MMP-7 are associated with impaired lung function and poorer survival in IPF patients 5.
AIM OF THE WORK
The purpose of this study was to measure the (MMP7) in RA patients with ILD and to assess for any correlation with RA-disease activity.
PATIENTS AND METHODS 1Study design and sample:
This study was cross sectional study included 40 RA patients fulfilling the To assess the strength of association between two quantitative variables. The correlation coefficient denoted symbolically "r" defines the strength (magnitude) and direction (positive or negative) of the linear relationship between two variables.  r= 0-0.19 is regarded as very weak correlation  r=0.2-0.39 as weak correlation  r=0.40-0.59 as moderate correlation  r=0.6-0.79 as strong correlation  r= 0.8-1 as very strong correlation P-value refers to level of significance as follows:
-P value >0.05 = insignificant. -P value < 0.05 = significant. -P value < 0.01 = highly significant. Independent t-test, ANOVA (analysis of variance) was used in relation analysis 6. The ROC Curve (Receiver Operating Characteristic) provides a useful way to evaluate the Sensitivity and specificity for quantitative Diagnostic measures that categorize cases into one of two groups. Serum MMP7 level ranged from 92.70-381.3 with means of (201.51±85.79), these levels are higher than normal range (0.16-10 ng/ml). Our 40 studied RA patients were divided into 2 groups: Group 1: RA patients without ILD which included 20 patients, Group 2: RA patients with ILD which included 20 patients.
RESULTS
Comparison between RA patients with and without ILD as regards serum MMP 7 showed that there was a highly significant difference between both groups (p<0.001) being higher in patients with ILD, coming in accordance with chen et al. study 8 who reported significant difference between both groups regarding the level of MMP7 (p=0.001) being higher among ILD patients.
On correlating serum MMP7 with joint affection, disease activity as measured by DAS score, among the studied RA patients (with and without ILD), it was found that, the S.MMP7 level showed positive correlation with duration of morning stiffness (p <0.001). While there was no significant correlation regarding other clinical parameters including DAS score. This was in agreement with moinzadeh et al.
9.
who found highly significant positive correlation regarding morning stiffness (p=0.031).
SUMMARY AND CONCLUSION
In conclusion our study showed that S. MMP7 can be used as a screening test for detection of interstitial lung disease in patients with rheumatoid arthritis, In our study, serum MMP7 level was higher in RA patients with ILD than patients without, but there were no statically significant relation regarding clinical and laboratory assessment of disease activity. So MMP7 might be specific to lung diseases.
RECOMMENDATIONS
Rheumatoid Arthritis patients should be followed up carefully by good history taking, prompt clinical examination and the required specific investigations in each follow up visit, Interstitial lung diseases is a common extra articular manifestation that increase the morbidity among RA patients.
RA patients with pulmonary manifestations (dry cough, exertional dyspnea, wheezy chest) should undergo further evaluation for detection of ILD.
Serum MMP7 may be used as screening test of RA patients for detection of ILD.
